ArticleFrontiers in immunology2026
Prognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The real-world efficacy and prognostic factors of First-line and subsequent-line treatment for first-recurrent/metastatic esophageal squamous cell cancer (ESCC) have not been fully evaluated. Methods: This single-institutional retrospective cohort study evaluated 156 first-recurrent/metastatic ESCC patients treated with First-line and subsequent-line treatment between January 2018 to January 2023. We assessed tumor response, long-term survival, and prognostic factors. Results: Among 156 ESCC patients with measurable lesions, in the first-line treatment setting, the combined Immunotherapy+Radiotherapy+Chemotherapy (IT+RT+CT) group had a lower incidence of progressive disease (PD) and Death compared with the Chemotherapy+Immunotherapy (CT+IT) group (80.0% vs 90.6%). First-Line Treatment were independent factors that affect progression-free survival (PFS), better PFS in the IT+RT+CT group compared to the CT+IT group (HR: 0.50, 95%CI: 0.28-0.90, P = 0.020). In the First-line and subsequent-line treatments, IT+RT+CT were identified as significant prognostic factors of overall survival (OS) through Cox proportional hazards analysis. After inverse probability of treatment weighting (IPTW) between the IT+RT+CT group and the CT+IT group in the First-line and Subsequent-line Treatments, the 1-, 2-year OS were 76.2% and 46.5% in the IT+RT+CT group, and 1-, 2-year OS were 39.5% and 19.4% in the CT+IT group, respectively (P = 0.011). In the doubly robust Cox proportional hazards model, which incorporated IPTW with weight trimming and adjustment for residual confounders (SMD>0.1), in the First-line and Subsequent-line Treatments, the IT+RT+CT regimen was significantly associated with improved OS compared to the CT+IT regimen (HR: 0.48, 95%CI: 0.27-0.85, P = 0.011). Conclusions: Our study demonstrated that, IT+RT+CT as first-line treatment for recurrent/metastatic ESCC significantly prolonged PFS compared to CT+IT. Furthermore, IT+RT+CT extended OS in First-line and subsequent-line treatments. However, these findings require validation in prospective studies to confirm their clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.